Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Highlights Pioglitazone Fracture Risk In “Dear Healthcare Provider” Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA issues MedWatch alert March 9, the second time the agency has warned of fracture risk in women taking thiazolidinediones in recent weeks.

You may also be interested in...



GSK “Dear Health Care Provider” Letter Cites Rosiglitazone Fracture Risk In Women

FDA MedWatch alert issued Feb. 20 notes there were “significantly more” fractures in women taking rosiglitazone in the ADOPT trial.

Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure

Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.

MADIT-CRT Data Support Expanded Cardiac Resynchronization Market

The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.

Topics

UsernamePublicRestriction

Register

PS065870

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel